Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
30 participants
INTERVENTIONAL
2008-02-29
2009-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
dexamethazone
injection form, 8 miligram, injected once
2
dexamethazone
injection form, 8 miligram, injected once
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
dexamethazone
injection form, 8 miligram, injected once
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Migraine without aura; at least 5 attack with mean duration of 4 to 72 hours and 2 of following:
* Unilateral
* Pulsatile
* Severe enough to impair daily activity
* Aggravate with walking and climbing, also 1 of following:
* Nausea and or vomiting
* Photophobia and phonophobia, and not contributed to other headache.
3. Migraine with aura; at least 2 attacks with 3 of following:
* One reversible aura
* Aura became apparent at least in 4 minutes
* Aura not lasting more than 60 minutes
* Headache develops in less than 60 minutes after aura
Exclusion Criteria
2. Ischemic heart disease
3. Basilar migraine with sign and symptoms such as:
* Diplopia
* Ataxia
* Dysarthria
* Dysphagia
* Weakness
* Sensory disorder
* Drowsiness
4. Peripheral vascular disease
5. Sepsis
6. Age more than 40 and less than 15 year old
7. Pregnancy
8. Use of triptans and ergots derivatives in past 24 hours
15 Years
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shiraz University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shiraz university of medical sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peyman Petramfar
Shiraz, Fars, Iran
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
212110
Identifier Type: -
Identifier Source: org_study_id